Skip to main content
. 2024 Jun 10;7(3):387–400. doi: 10.31662/jmaj.2023-0214

Table 4.

Changes in Health-Related QOL Evaluation Parameters before and after Empagliflozin and Linagliptin Combination Therapy.

Variable Overall
(n = 39)
DPP4i add-on group (n = 20) SGLT2i add-on group (n = 19) P
Adherence to medication score
 Baseline 7 (6-7) 7 (6-7) 7 (6-7) 0.98
 24 weeks 7 (6-7) 7 (6-7) 7 (6-7) 0.93
 Change level 0 (0-0) 0 (0-0) 0 (0-0) 0.64
 p§ 0.72 >0.99 >0.99
Geriatric Depression Scale 5, total score
 Baseline 1 (0-3) 1 (0-2) 0 (0-3) 0.25
 24 weeks 1 (0-2) 1 (0-2) 2 (1-3) 0.12
 Change level 0 (−0.75 to 0) 0 (−0.5 to 0) 0 (−1 to 0) 0.91
 p§ 0.32 0.35 0.50
International Physical Activity Questionnaire Short Form 2, total physical activity score
 Baseline 792 (240-2,919) 1,053 (478-4,345) 438 (66-2,772) 0.050
 24 weeks 720 (240-2,200) 1,369 (320-3,308) 540 (135-1,260) 0.16
 Change level 0 (−300-342) 21 (−573-722.5) 0 (−172-310) >0.99
 p§ 0.59 0.76 0.57

Continuous variables are expressed as median (interquartile range (IQR)). †, adherence-medication score was calculated by analyzing questionnaires about medication from the participants. The difference in values between the DPP4i and SGLT2i add-on groups was analyzed using Mann-Whitney U test (‡). Comparison of each value between baseline and 24 weeks was performed using Wilcoxon signed-rank test (§).

DPP4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium-glucose cotransporter-2 inhibitor